Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Status:
Terminated
Trial end date:
2016-05-28
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well giving rasburicase together with allopurinol
works in treating patients with hematologic malignancies. Rasburicase may reduce the level of
uric acid in the blood. Allopurinol may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. It is not yet known which dose of rasburicase is more
effective in treating hematologic malignancies when given together with or without
allopurinol.